Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1449
The sale and assignment of Lotemax and Alrex.
Lotemax is a topical, site-specific steroid that is used to treat steroid responsive inflammatory eye conditions. The prescription eye drop is also used for post-operative eye inflammations such as experienced following cataract surgery. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, thereby increasing its safety profile.
Alrex is a specially developed formula of loteprednol etabonate that is used in the treatment of ophthalmic allergies. Alrex is indicated for the treatment of seasonal allergic conjunctivitis, an inflammation of the eye usually caused by pollens. Seasonal allergic conjunctivitis produces itching, tearing, redness and swelling in the conjunctiva, the membrane that covers the inside of the eyelid and the white part of the eye.
IPSCIO Record ID: 25877
IPSCIO Record ID: 27849
The Licensor also recently enhanced its economic interest in Prednisporin and the other product candidates Licensed to Licensee for ophthalmic development.
Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the eye) due to allergy. Although allergens differ between patients, the most common cause is hay fever. Symptoms consist of redness (mainly due to vasodilation of the peripheral small blood vessels), oedema of the conjunctiva, itching and increased lacrimation (production of tears). If this is combined with rhinitis, the condition is termed allergic rhinoconjunctivitis.
Prednisporin(TM) is the first combination therapy developed for the treatment of persistent allergic conjunctivitis. Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the eye) due to allergy. Although allergens differ between patients, the most common cause is hay fever. Symptoms consist of redness (mainly due to vasodilation of the peripheral small blood vessels), oedema of the conjunctiva, itching and increased lacrimation (production of tears). If this is combined with rhinitis, the condition is termed allergic rhinoconjunctivitis.
IPSCIO Record ID: 243505
Technology shall mean, collectively, all forms and formulations, all methods of manufacture or use thereof, and all data, information, compositions, formulae, procedures, protocols, techniques and results of experimentation and testing and other technology relating to or reasonably necessary or useful to make, use, sell, offer for sale, import, develop, seek regulatory approval, market, commercialize or otherwise exploit the foregoing.
EM-100 is an ophthalmic product indicated for the treatment of allergic conjunctivitis. EM-100 is a unique formulation of an already FDA-approved molecule that is widely used for allergic conjunctivitis.
Allergic conjunctivitis is an eye inflammation caused by an allergic reaction to substances like pollen or mold spores. The inside of your eyelids and the covering of your eyeball have a membrane called the conjunctiva. The conjunctiva is susceptible to irritation from allergens, especially during hay fever season.
IPSCIO Record ID: 282937
The license granted to Licensee herein shall not include the right to grant further licenses or sub-licenses to any third party without the prior written consent of Licensor, such consent not to be unreasonably withheld. Nothing in this Agreement shall affect, and Licensor shall retain the right to grant, other sub-licenses to the Product outside of the Territory.
5,556,848 – Ophthalmic suspension containing diflupredonate
6,114,319 – Compositions containing difluprednate
Product shall mean the topical corticosteroid ophthalmic emulsion and/or suspension containing the Compound as an active ingredient for the treatment of ophthalmic diseases in humans only. Combination products containing the Compound and other active ingredients, whether patented or not, are initially excluded from this definition, but may be included only with the express prior written consent of Licensor, such consent not to be unreasonably withheld. Furthermore, Licensor has the right to amend this Agreement in exchange for the grant of permission to allow a patented combination product into this definition, provided however, that for the term of this Agreement, there shall be a royalty on sales of combination products identical to those on the Product. After the term of this Agreement ends, the Parties shall negotiate in good faith for the future terms of such a grant.
Compound shall mean a certain chemical substance having the chemical structure of 6Ã¡, 9-Difluoro- 11 Ã¢, 17, 2 1-trihydroxy-1, 4-pregnadiene-3, 20-dione 21-acetate 17-butyrate. The Compound as also referred to as â€œDifluprednate.â€